People suffering from psoriasis reported quick and extensive improvement of the psoriasis skin condition with new drug. The study published in The Lancet journal. 40% of people reported a complete clearance of psoriatic plaques after 12 weeks of treatment with the new drug and over 90% showed improvement.
Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients requiring urgent anticoagulant reversal. No safety concerns relating to idarucizumab* were identified. The results have been simultaneously published in the New England Journal of Medicine (NEJM) and presented today at the International Society of Thrombosis and Haemostasis 2015 Congress in Toronto, Canada.
[adsense:336x280:8701650588]


